MarketBeat on MSN3d
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...
Regeneron Pharmaceuticals Unusual Options Activity For February 25
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...
Yahoo Finance13d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Sanofi and Regeneron’s blockbuster biologic Dupixent ... Dupixent, a fully human monoclonal antibody, inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways ...
Nasdaq2d
Regeneron: CHMP Recommends Conditional Marketing Authorization Of Linvoseltamab
(RTTNews) - Regeneron Pharmaceuticals (REGN ... an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...